Herein I discuss the therapeutic potential of targeting certain ceramide synthase isoforms for the treatment of obesity, insulin resistance, steatohepatitis, and other metabolic disorders. The gene discussed is TLCD3B; the disease is obesity due to melanocortin 4 receptor deficiency.